United Kingdom (UK)
Recombinant monoclonal antibody to CD20. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the hybridoma 1F5.
UniProt Accession Number of Target Protein: P11836
Alternative Name(s) of Target: MS4A1; B-lymphocyte antigen CD20; B-lymphocyte surface antigen B1; Bp35; Leukocyte surface antigen Leu-16; Membrane-spanning 4-domains subfamily A member 1; E9PPL6; P19437
Immunogen: This antibody was raised by hyperimmunising BALB/c mice with the Raji Burkett's lymphoma line and the NALM-6 pre B leukaemia line.
Specificity: This antibody is specific for CD20, which is expressed by normal and malignant B cells.
Application Notes: This antibody, either alone or in combination with T cell derived factors, induces B cell proliferation via CD20 cross-linking (Clark et al, 1985).When administered to patients with refractory malignant B cell lymphomas, this antibody depletes circulating and lymph node tumour cells, with minimal toxicity (Press et al, 1987). A murine/human chimeric IgG1 construct of this antibody has been shown to lyse Burkitt's lymphoma (5RAJI) cells (Stockmeyer et al, 2000), while IgG1 and IgA2 isotypes of this antibody have been shown to kill B cells in vitro and in deplete B cells in vivo (Lohse et al, 2018). The humanized version of this antibody can be provided upon request.
Antibody first published in:
Ledbetter et al. Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets Human Immunology, 1986, Vol.15(1), pp.30-43 PMID:2419284
Note on publication:
Describes the original generation of this antibody.